On April 8, 2022 Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, reported that the novel data it is presenting at the American Association of Cancer Research’s annual meeting in New Orleans on April 12th, 2022 is now available on both the AACR (Free AACR Whitepaper) and Cytovia websites (Press release, Cytovia Therapeutics, APR 8, 2022, View Source [SID1234611775]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased with the decisive progress of Cytovia’s R&D team towards the manufacturing and preclinical validation of its two synergistic platforms," commented Dr. Daniel Teper, CEO and Chairman of Cytovia Therapeutics. "The data presented at AACR (Free AACR Whitepaper) supports the advancement of our lead GPC3-targeting hepatocellular carcinoma (HCC) program towards clinical trials and our differentiated CD38-targeting multiple myeloma program to IND-enabling studies. Cytovia is the first company to combine its own iPSC-derived natural killer (iNK) cells and multispecific, NK cell-engaging antibodies and is building a pipeline that encompasses both hematological malignancies and solid tumors."

"Cytovia’s GPC3-directed NK-engager in combination with iPSC-derived NK cells demonstrated impressive anti-tumor activity in mice that merits clinical development," added Dr. Michael Friedman, a member of Cytovia’s Board of Directors. "For the large number of hepatocellular cancer patients who currently have such limited, poor clinical options, a novel tumor antigen-directed NK engager is needed. It would be a welcome addition to a physician’s armament, with high potential for numerous combinations. The early CYT-338 data, showing superiority over daratumumab in several in vitro assays, is similarly impressive and warrants further preclinical development in my opinion."

Highlights from Posters Presented at the AACR (Free AACR Whitepaper) Annual Meeting

CYT-303

The FLEX-NKTM tetravalent, multifunctional antibody CYT-303 directed against NKp46 and GPC3 demonstrated in vitro and in vivo activity against HCC tumor targets.
iNK cells expressed a favorable combination of multiple activation and few inhibitory receptors that corresponded to more potent cytolytic activity against HCC targets.
The combination of the FLEX-NKTM and iNK platforms demonstrated greater in vitro and in vivo anti-tumor activity in HCC models than iNK cells alone, with a favorable in vitro cytokine release and immune cell subset safety profile.
These preclinical proof of concept studies with CYT-303 alone or in combination with iNK cells in HCC warrant clinical development.
CYT-338

The FLEX-NKTM multifunctional engager antibody CYT-338 directed against NKp46 and CD38 demonstrated in vitro activity against multiple myeloma tumor targets.
An analysis of binding sites on CD38 indicates CYT-338 binds an epitope that is distinct from daratumumab.
The binding, cytokine release, cytotoxicity, and fratricide profiles of CYT-338 were superior to daratumumab.
These data support further development of CYT-338 as a therapeutic for targeting CD38 expressing multiple myeloma cells.
For details on in-person poster presentations, please see the following:

Title: Preclinical characterization of FLEX-NKTM tetravalent NKp46 engager directed against GPC3 (CYT-303) alone or in combination with iPSC derived Natural Killer cells (iNKs) against hepatocellular carcinoma (HCC)
Presenter: Antonio Arulanandam
Session Title: Adoptive Cell Therapy
Session Date and Time: Tuesday, Apr 12, 2022, 9:00 AM – 12:30 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 30
Poster Board Number: 8
Permanent Abstract Number: 2752
Abstract Link

Title: Novel multifunctional tetravalent CD38 NKp46 FLEX NKTM engagers actively target and kill multiple myeloma cells
Presenter: Liang Lin
Session Title: Combination Immunotherapies / Therapeutic Antibodies
Session Date and Time: Tuesday, Apr 12, 2022, 1:30 PM – 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 32
Poster Board Number: 17
Permanent Abstract Number: 3436
Abstract Link